Progena Pancreas Plus

Acidum Phosphoricum, Berberis Vulgaris, Bilberry, Cheidonium Majus, Creosotum, Kidney, Natrum Sulpuricum, Pancreas, Syzygium Jambolanum


Meditrend, Inc. Dba Progena Professional Formulations
Human Otc Drug
NDC 62713-914
Progena Pancreas Plus also known as Acidum Phosphoricum, Berberis Vulgaris, Bilberry, Cheidonium Majus, Creosotum, Kidney, Natrum Sulpuricum, Pancreas, Syzygium Jambolanum is a human otc drug labeled by 'Meditrend, Inc. Dba Progena Professional Formulations'. National Drug Code (NDC) number for Progena Pancreas Plus is 62713-914. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Progena Pancreas Plus drug includes Berberis Vulgaris Root Bark - 2 [hp_X]/mL Bilberry - 2 [hp_X]/mL Chelidonium Majus - 4 [hp_X]/mL Phosphoric Acid - 4 [hp_X]/mL Pork Kidney - 6 [hp_X]/mL Sodium Sulfate - 6 [hp_X]/mL Sus Scrofa Pancreas - 6 [hp_X]/mL Syzygium Cumini Seed - 10 [hp_X]/mL Wood Creosote - 6 [hp_X]/mL . The currest status of Progena Pancreas Plus drug is Active.

Drug Information:

Drug NDC: 62713-914
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Progena Pancreas Plus
Also known as the trade name. It is the name of the product chosen by the labeler.
Proprietary Name Base: Progena
The base of the Brand/Proprietary name excluding its suffix.
Proprietary Name Suffix: Pancreas Plus
A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Acidum Phosphoricum, Berberis Vulgaris, Bilberry, Cheidonium Majus, Creosotum, Kidney, Natrum Sulpuricum, Pancreas, Syzygium Jambolanum
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Meditrend, Inc. Dba Progena Professional Formulations
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BERBERIS VULGARIS ROOT BARK - 2 [hp_X]/mL
BILBERRY - 2 [hp_X]/mL
CHELIDONIUM MAJUS - 4 [hp_X]/mL
PHOSPHORIC ACID - 4 [hp_X]/mL
PORK KIDNEY - 6 [hp_X]/mL
SODIUM SULFATE - 6 [hp_X]/mL
SUS SCROFA PANCREAS - 6 [hp_X]/mL
SYZYGIUM CUMINI SEED - 10 [hp_X]/mL
WOOD CREOSOTE - 6 [hp_X]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jan, 1985
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 19 May, 2024
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
UNII:
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
62713-914-0130 mL in 1 BOTTLE, DROPPER (62713-914-01)01 Jan, 1985N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.